Abstract
Certain Gram-positive bacteria, including meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and quinolone-resistant Streptococcus pneumoniae have achieved the status of "superbugs", in that there are few or no antibiotics available for therapy against these pathogens. Only a few classes of novel antibiotics have been introduced in the past 40 years, and all since 1999, including the streptogramin combination quinupristin/dalfopristin (Synercid), the oxazolidinone linezolid, and the lipopeptide daptomycin. This review discusses the mechanisms of antibiotic action against Gram-positive pathogens, and resistance counter-mechanisms developed by Gram-positive bacteria, with emphasis on the newer agents.
Original language | English |
---|---|
Pages (from-to) | 209-218 |
Number of pages | 10 |
Journal | Lancet Infectious Diseases |
Volume | 5 |
Issue number | 4 |
DOIs | |
Publication status | Published or Issued - Apr 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Infectious Diseases